Key result
In incident ESRD patients without cardiovascular disease, exposure to ACEi/ARBs plus β-blockers was associated with reduced all-cause mortality compared to no treatment (HR 0.68; 95% CI 0.61-0.77).
Why the study?
Does treatment with ACEi/ARBs, β-blockers, or both reduce all-cause mortality in incident ESRD patients without known cardiovascular disease?
Cohort (n=13,741)
Yes
Does treatment with ACEi/ARBs, β-blockers, or both reduce all-cause mortality in incident ESRD patients without known cardiovascular disease?
Hazard Ratio: 0.68 (95% CI 0.61–0.77)
Absolute Event Rate: 5.8% vs 7.8%
Neurohormonal blockade with ACEi/ARBs, beta-blockers, or both is associated with reduced all-cause mortality in incident ESRD patients without known cardiovascular disease.
May support ACEi/ARB plus β-blocker use in incident ESRD without CVD; leaves open randomized confirmation.
BACKGROUND: End-stage renal disease (ESRD) patients even without known cardiovascular (CV) disease have high mortality rates. Whether neurohormonal blockade treatments improve outcomes in this population remains unknown. The aim of this study was to assess the effect of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), β-blockers or both in all-cause mortality rates in incident ESRD patients without known CV disease starting renal replacement therapy (RRT) between 2009 and 2015 in the nationwide Réseau Epidémiologie et Information en Néphrologie registry. METHODS: Patients with known CV disease and those who started emergency RRT, stopped RRT or died within 6 months were excluded. Propensity score matching models were used. The main outcome was all-cause mortality. RESULTS: A total of 13 741 patients were included in this analysis. The median follow-up time was 24 months. When compared with matched controls without antihypertensive treatment, treatment with ACEi/ARBs, β-blockers and ACEi/ARBs + β-blockers was associated with an event-rate reduction per 100 person-years: ACEi/ARBs 7.6 [95% confidence interval (CI) 7.1-8.2] versus matched controls 9.5 (8.8-10.1) [HR 0.76 (95% CI 0.69-0.84)], β-blocker 7.1 (6.6-7.7) versus matched controls 9.5 (8.5-10.2) [HR 0.72 (0.65-0.80)] and ACEi/ARBs + β-blockers 5.8 (5.4-6.4) versus matched controls 7.8 (7.2-8.4) [HR 0.68 (0.61-0.77)]. CONCLUSIONS: Neurohormonal blocking therapies were associated with death rate reduction in incident ESRD without CV disease. Whether these relationships are causal will require randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2018) conducted a cohort in Incident end-stage renal disease without cardiovascular disease (n=13,741). ACEi/ARBs and/or β-blockers vs. Matched controls without antihypertensive treatment was evaluated on All-cause mortality (HR 0.68, 95% CI 0.61-0.77). In incident ESRD patients without cardiovascular disease, exposure to ACEi/ARBs plus β-blockers was associated with reduced all-cause mortality compared to no treatment (HR 0.68; 95% CI 0.61-0.77).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: